Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report

IF 0.2 Q4 ONCOLOGY Current problems in cancer. Case reports Pub Date : 2025-01-11 DOI:10.1016/j.cpccr.2025.100349

Jialin Qian, Tianqing Chu

{"title":"Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report","authors":"Jialin Qian, Tianqing Chu","doi":"10.1016/j.cpccr.2025.100349","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance.</div></div><div><h3>Case description</h3><div>A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled.</div></div><div><h3>Conclusions</h3><div>Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100349"},"PeriodicalIF":0.2000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621925000018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance.

Case description

A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled.

Conclusions

Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Lorlatinib治疗alk阳性非小细胞肺癌的长期疗效和安全性：1例报告

肿瘤淋巴瘤激酶（ALK）重排是促进非小细胞肺癌（NSCLC）中ALK蛋白表达的关键致癌驱动因素。ALK酪氨酸激酶抑制剂（TKIs）显著提高了生存效益。探索ALK+ NSCLC患者的最佳治疗方案具有重要的临床意义。病例描述：一名67岁女性，无吸烟史，首次诊断为局部晚期ALK+肺腺癌（IIIC期）。患者入组CROWN研究，随机接受氯拉替尼治疗，1个月后复查肺部病变明显减轻。疗效为PR，末次随访时PFS达72个月。治疗期间患者耐受性良好，未发生严重不良事件，肿瘤得到有效控制。结论索拉替尼是晚期alk阳性NSCLC患者有效的1 L治疗方案，可为患者带来长期获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊